It's incredible that the market cap of BioCryst is around the...

It's incredible that the market cap of BioCryst is around the same as that of BTA. BioCryst have IV peramivir; BTA have IV Relenza, which is probably at least as effective as peramivir, given that the latter will have the same problems with resistance as Tamiflu. So, on the basis of IV Relenza alone, BTA should be valued at least as much as BioCryst. But BTA also has inhaled Relenza, a vastly larger market than that for IV Relenza, as well as LANI in Phase II clinical trials. If the BioCryst share price is justified then the BTA share price should be ten times what it currently is.